Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatientsA Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
Ahmad T, Riello RJ, Inzucchi SE. A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review 2021, 16: e11. PMID: 33897837, PMCID: PMC8054345, DOI: 10.15420/ecr.2020.01.r1.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsType 2 diabetesCardiovascular diseaseHigh-risk type 2 diabetes patientsGlucagon-like peptide-1 receptor agonistsMajor adverse cardiovascular eventsSpecific glucose-lowering agentsPeptide-1 receptor agonistsRecent clinical trial dataType 2 diabetes patientsAdverse cardiovascular eventsHeart failure hospitalizationGlucose-lowering agentsClinical trial dataAnti-diabetes drugsCardiovascular eventsCardiovascular outcomesDiabetes medicationsFailure hospitalizationCardiovascular riskHeart failurePharmacological treatmentSafe prescribingDiabetes patients